Welcome to LookChem.com Sign In|Join Free
  • or
2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine is a complex organic compound characterized by its white to off-white solid appearance. It features a unique molecular structure with a phenyl group connected to a butenyl chain, which is further attached to a phenoxy group. 2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine is known for its antineoplastic properties, making it a potential candidate for pharmaceutical applications.

13002-65-8

Post Buying Request

13002-65-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

13002-65-8 Usage

Uses

Used in Pharmaceutical Industry:
2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine is used as an antineoplastic agent for its potential cancer-fighting properties. It is particularly valuable in the development of treatments for various types of cancer due to its ability to target and inhibit the growth of cancer cells.
Used in Drug Development:
In the field of drug development, 2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine serves as a key compound in the research and design of new pharmaceuticals. Its unique chemical structure and antineoplastic properties make it a promising candidate for the creation of innovative cancer therapies.
Used in Cancer Research:
2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine is utilized in cancer research to better understand the mechanisms of cancer growth and progression. By studying the interactions of 2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine with cancer cells, researchers can gain insights into potential therapeutic targets and develop more effective treatments.
Chemical Properties:
The chemical properties of 2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine include its white to off-white solid state, which is indicative of its stability and purity. Its molecular structure, featuring a phenyl group, butenyl chain, and phenoxy group, contributes to its antineoplastic activity and potential use in various pharmaceutical applications.

Check Digit Verification of cas no

The CAS Registry Mumber 13002-65-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,0,0 and 2 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 13002-65:
(7*1)+(6*3)+(5*0)+(4*0)+(3*2)+(2*6)+(1*5)=48
48 % 10 = 8
So 13002-65-8 is a valid CAS Registry Number.
InChI:InChI=1/C28H32/c1-4-27(24-14-7-5-8-15-24)28(25-16-9-6-10-17-25)26-20-18-23(19-21-26)13-11-12-22(2)3/h5-10,14-22H,4,11-13H2,1-3H3/b28-27+

13002-65-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine

1.2 Other means of identification

Product number -
Other names UPCMLD-DP027:001

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:13002-65-8 SDS

13002-65-8Synthetic route

ICI 77949
69967-79-9

ICI 77949

(2-chloroethyl)dimethylamine hydrochloride
4584-46-7

(2-chloroethyl)dimethylamine hydrochloride

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
With potassium carbonate In ethanol; toluene at 80 - 85℃; for 3h; Inert atmosphere;97%
With sodium ethanolate In ethanol for 24h; Heating;62%
With sodium hydride 1.) DMF, 2.) 60 deg C, 30 min; Yield given. Multistep reaction;
[2-(4-iodophenoxy)ethyl]dimethylamine
93790-54-6

[2-(4-iodophenoxy)ethyl]dimethylamine

(Z)-2-(1,2-diphenylbut-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
624731-39-1

(Z)-2-(1,2-diphenylbut-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
With sodium hydroxide; bis(tri-t-butylphosphine)palladium(0) In tetrahydrofuran at 60℃; for 24h; Suzuki-Miyaura coupling;95%
With sodium hydroxide; bis(tri-t-butylphosphine)palladium(0) In tetrahydrofuran at 60℃; for 24h; Suzuki-Miyaura coupling;95%
iodobenzene
591-50-4

iodobenzene

(Z)-1-(4',4',5',5'-tetramethyl-1',3',2'-dioxaborolan-2'-yl)-1-[4''-(2'''-dimethylaminoethoxy)phenyl]-2-phenyl-1-butene
865999-31-1

(Z)-1-(4',4',5',5'-tetramethyl-1',3',2'-dioxaborolan-2'-yl)-1-[4''-(2'''-dimethylaminoethoxy)phenyl]-2-phenyl-1-butene

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
With sodium hydroxide; bis(tri-t-butylphosphine)palladium(0) In tetrahydrofuran at 60℃; for 24h;75%
(E)-1,2-diphenylbut-1-en-1-yl dimethylcarbamate

(E)-1,2-diphenylbut-1-en-1-yl dimethylcarbamate

(4-(2-(dimethylamino)ethoxy)phenyl)magnesium bromide
35258-27-6

(4-(2-(dimethylamino)ethoxy)phenyl)magnesium bromide

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
With N,N'-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene hydrochloride; palladium diacetate In tetrahydrofuran at 50℃; for 18h; Schlenk technique; Inert atmosphere; Sealed tube; stereoselective reaction;70%
(E)-1,2-diphenyl-1-butene boronic acid
918793-63-2

(E)-1,2-diphenyl-1-butene boronic acid

[2-(4-bromophenoxy)ethyl]dimethylamine
2474-07-9

[2-(4-bromophenoxy)ethyl]dimethylamine

A

1,2-diphenyl-butan-1-one
16282-16-9

1,2-diphenyl-butan-1-one

B

tamoxifen
10540-29-1

tamoxifen

C

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
With sodium carbonate; tetrakis(triphenylphosphine) palladium(0) In 1,2-dimethoxyethane; water Suzuki-Miyaura cross-coupling; Heating;A n/a
B 65%
C n/a
N,N-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine
873078-93-4

N,N-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine

(2R,3R)-2-ethyl-2,3-diphenyloxirane

(2R,3R)-2-ethyl-2,3-diphenyloxirane

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Stage #1: (2R,3R)-2-ethyl-2,3-diphenyloxirane With N,N,N,N,-tetramethylethylenediamine; tert.-butyl lithium In diethyl ether; pentane at -78℃; for 0.25h;
Stage #2: N,N-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine In diethyl ether at 20 - 38℃;
63%
2-(dimethylamino)ethyl chloride
107-99-3

2-(dimethylamino)ethyl chloride

(E,Z)-4-(1,2-diphenylbut-1-en-1-yl)phenol
68684-63-9

(E,Z)-4-(1,2-diphenylbut-1-en-1-yl)phenol

A

tamoxifen
10540-29-1

tamoxifen

B

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 50℃; for 0.5h;A 51%
B 44%
With sodium hydride In N,N-dimethyl-formamide at 50℃; for 0.5h;
4-(4-[2-dimethylaminoethoxy]phenyl)-3,4-diphenylbut-1-ene

4-(4-[2-dimethylaminoethoxy]phenyl)-3,4-diphenylbut-1-ene

A

tamoxifen
10540-29-1

tamoxifen

B

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
With potassium tert-butylate In dimethyl sulfoxide at 20℃; for 1h;A 39%
B 37%
(1-phenylpropyl)phosphonic acid di-o-tolyl ester
872254-52-9

(1-phenylpropyl)phosphonic acid di-o-tolyl ester

(4-(2-(dimethylamino)ethoxy)phenyl)(phenyl)methanone
51777-15-2

(4-(2-(dimethylamino)ethoxy)phenyl)(phenyl)methanone

A

tamoxifen
10540-29-1

tamoxifen

B

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Stage #1: (1-phenylpropyl)phosphonic acid di-o-tolyl ester With n-butyllithium In tetrahydrofuran; hexane at -78℃; for 1h;
Stage #2: (4-(2-(dimethylamino)ethoxy)phenyl)(phenyl)methanone In tetrahydrofuran; hexane at -78℃; for 48h; Horner reaction;
A 28%
B 12%
tamoxifen
10540-29-1

tamoxifen

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
With hydrogenchloride In ethanol for 4h; Heating;
ICI 77949
69967-79-9

ICI 77949

(2-chloroethyl)dimethylamine hydrochloride
4584-46-7

(2-chloroethyl)dimethylamine hydrochloride

A

tamoxifen
10540-29-1

tamoxifen

B

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
With sodium methylate; hydrogen cation Yield given. Multistep reaction. Yields of byproduct given. Title compound not separated from byproducts;
(1S,2R)-1-[4-(2-Dimethylamino-ethoxy)-phenyl]-1,2-diphenyl-butan-1-ol
748-97-0, 77542-06-4, 77542-07-5, 81992-83-8, 111914-74-0

(1S,2R)-1-[4-(2-Dimethylamino-ethoxy)-phenyl]-1,2-diphenyl-butan-1-ol

A

tamoxifen
10540-29-1

tamoxifen

B

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
With hydrogenchloride In ethanol for 0.333333h; Heating; Yield given;
[2-(4-bromophenoxy)ethyl]dimethylamine
2474-07-9

[2-(4-bromophenoxy)ethyl]dimethylamine

triethylaluminum
97-93-8

triethylaluminum

diphenyl acetylene
501-65-5

diphenyl acetylene

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
tetrakis(triphenylphosphine) palladium(0) 1.) hexane, toluene, 90 deg C, 24 h, 2.) THF, reflux, 24 h; Yield given. Multistep reaction;
1-phenyl-1-butyne
622-76-4

1-phenyl-1-butyne

[2-(4-iodophenoxy)ethyl]dimethylamine
93790-54-6

[2-(4-iodophenoxy)ethyl]dimethylamine

p-I-C6H4-Si(Me2)CH2CH2CONH-resin

p-I-C6H4-Si(Me2)CH2CH2CONH-resin

A

tamoxifen
10540-29-1

tamoxifen

B

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

C

{2-[4-(1-Benzhydrylidene-propyl)-phenoxy]-ethyl}-dimethyl-amine

{2-[4-(1-Benzhydrylidene-propyl)-phenoxy]-ethyl}-dimethyl-amine

Conditions
ConditionsYield
With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium hydroxide; 3,5-dimethoxyphenol; tetrakis(triphenylphosphine)platinum; trifluoroacetic acid; bis(pinacol)diborane 1.) DMF, 80 deg C, 2.) DME, 25 deg C, 18 h, 3.) 25 deg C, 18 h, 4.) CH2Cl2; Yield given. Multistep reaction. Yields of byproduct given. Title compound not separated from byproducts;
1-phenyl-1-butyne
622-76-4

1-phenyl-1-butyne

4-tolyl iodide
624-31-7

4-tolyl iodide

p-I-C6H4-Si(Me2)CH2CH2CONH-resin

p-I-C6H4-Si(Me2)CH2CH2CONH-resin

A

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

B

(Z)-(1-(p-tolyl)but-1-ene-1,2-diyl)dibenzene
116454-42-3

(Z)-(1-(p-tolyl)but-1-ene-1,2-diyl)dibenzene

C

{2-[4-(1-Benzhydrylidene-propyl)-phenoxy]-ethyl}-dimethyl-amine

{2-[4-(1-Benzhydrylidene-propyl)-phenoxy]-ethyl}-dimethyl-amine

Conditions
ConditionsYield
With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium hydroxide; 3,5-dimethoxyphenol; tetrakis(triphenylphosphine)platinum; trifluoroacetic acid; bis(pinacol)diborane 1.) DMF, 80 deg C, 2.) DME, 25 deg C, 18 h, 3.) 25 deg C, 18 h, 4.) CH2Cl2, 10 min; Yield given. Multistep reaction. Yields of byproduct given. Title compound not separated from byproducts;
1-phenyl-1-butyne
622-76-4

1-phenyl-1-butyne

4-tolyl iodide
624-31-7

4-tolyl iodide

p-I-C6H4-Si(Me2)CH2CH2CONH-resin

p-I-C6H4-Si(Me2)CH2CH2CONH-resin

A

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

B

C23H21I

C23H21I

C

{2-[4-(1-Benzhydrylidene-propyl)-phenoxy]-ethyl}-dimethyl-amine

{2-[4-(1-Benzhydrylidene-propyl)-phenoxy]-ethyl}-dimethyl-amine

Conditions
ConditionsYield
With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium hydroxide; 3,5-dimethoxyphenol; tetrakis(triphenylphosphine)platinum; Iodine monochloride; bis(pinacol)diborane 1.) DMF, 80 deg C, 2.) DME, 25 deg C, 18 h, 3.) 25 deg C, 18 h, 4.) CH2Cl2, 30 min; Yield given. Multistep reaction. Yields of byproduct given. Title compound not separated from byproducts;
iodobenzene
591-50-4

iodobenzene

Z-(Et)(C6H5)CC(4-Me2NCH2CH2OC6H4)(B(pin))

Z-(Et)(C6H5)CC(4-Me2NCH2CH2OC6H4)(B(pin))

A

tamoxifen
10540-29-1

tamoxifen

B

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

C

Dimethyl-{2-[4-((Z)-2-phenyl-but-1-enyl)-phenoxy]-ethyl}-amine

Dimethyl-{2-[4-((Z)-2-phenyl-but-1-enyl)-phenoxy]-ethyl}-amine

Conditions
ConditionsYield
With sodium hydroxide; bis(tri-t-butylphosphine)palladium(0) In tetrahydrofuran at 60℃; for 24h; Product distribution; Further Variations:; Reagents; Suzuki-Miyaura coupling;
(2-chloroethyl)dimethylamine hydrochloride
4584-46-7

(2-chloroethyl)dimethylamine hydrochloride

(E,Z)-4-(1,2-diphenylbut-1-en-1-yl)phenol
68684-63-9

(E,Z)-4-(1,2-diphenylbut-1-en-1-yl)phenol

A

tamoxifen
10540-29-1

tamoxifen

B

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
With sodium ethanolate In ethanol for 24h; Heating; Title compound not separated from byproducts;
Stage #1: 1-(4-hydroxyphenyl)-1,2-diphenylbut-1-ene With sodium hydride In tetrahydrofuran; mineral oil at 0 - 20℃;
Stage #2: (2-chloroethyl)dimethylamine hydrochloride With potassium iodide In tetrahydrofuran; mineral oil for 12h; Reflux; Overall yield = 80 %; Overall yield = 148.5 mg; Optical yield = 8.108 %de;
diphenyl acetylene
501-65-5

diphenyl acetylene

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: tetrahydrofuran; dibutyl ether / 2 h / -10 °C
1.2: 51 percent / triisopropyl borate / tetrahydrofuran; dibutyl ether / -78 - 20 °C
2.1: sodium carbonate / Pd(PPh3)4 / 1,2-dimethoxy-ethane; H2O / Heating
View Scheme
(1-(4-methoxyphenyl)but-1-ene-1,2-diyl)dibenzene
69967-78-8

(1-(4-methoxyphenyl)but-1-ene-1,2-diyl)dibenzene

ethanolic KOH

ethanolic KOH

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: BBr3 / CH2Cl2 / 5 h / -60 - 20 °C
2: EtONa / ethanol / 24 h / Heating
View Scheme
1-((Z)-1,2-Diphenyl-buta-1,3-dienyl)-4-methoxy-benzene
857085-82-6

1-((Z)-1,2-Diphenyl-buta-1,3-dienyl)-4-methoxy-benzene

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: aq. H2O2; N2H4*H2O / ethanol; CH2Cl2 / -60 - 20 °C
2: BBr3 / CH2Cl2 / 5 h / -60 - 20 °C
3: EtONa / ethanol / 24 h / Heating
View Scheme
1,1-bis(4',4',5',5'-tetramethyl-1',3',2'-dioxaborolan-2'-yl)-2-phenyl-1-butene
865999-18-4

1,1-bis(4',4',5',5'-tetramethyl-1',3',2'-dioxaborolan-2'-yl)-2-phenyl-1-butene

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 55 percent / Pd2(dba)3; P(t-Bu)3; aq. KOH / tetrahydrofuran / 5 h / 20 °C
2: 75 percent / Pd[P(t-Bu)3]2; aq. NaOH / tetrahydrofuran / 24 h / 60 °C
View Scheme
[2-(4-iodophenoxy)ethyl]dimethylamine
93790-54-6

[2-(4-iodophenoxy)ethyl]dimethylamine

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 55 percent / Pd2(dba)3; P(t-Bu)3; aq. KOH / tetrahydrofuran / 5 h / 20 °C
2: 75 percent / Pd[P(t-Bu)3]2; aq. NaOH / tetrahydrofuran / 24 h / 60 °C
View Scheme
1-Phenyl-1-propanol
93-54-9

1-Phenyl-1-propanol

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: 95 percent / PBr3 / CH2Cl2 / 20 °C
2.1: 120 h / 130 °C
2.2: 45 percent / NaOH / H2O / 20 °C
3.1: n-butyllithium / tetrahydrofuran; hexane / 1 h / -78 °C
3.2: 12 percent / tetrahydrofuran; hexane / 48 h / -78 °C
View Scheme
1-bromopropylbenzene
2114-36-5, 101308-38-7

1-bromopropylbenzene

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: 120 h / 130 °C
1.2: 45 percent / NaOH / H2O / 20 °C
2.1: n-butyllithium / tetrahydrofuran; hexane / 1 h / -78 °C
2.2: 12 percent / tetrahydrofuran; hexane / 48 h / -78 °C
View Scheme
4-Hydroxybenzophenone
1137-42-4

4-Hydroxybenzophenone

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: 90 percent / sodium ethoxide / ethanol / 24 h / Heating
2.1: n-butyllithium / tetrahydrofuran; hexane / 1 h / -78 °C
2.2: 12 percent / tetrahydrofuran; hexane / 48 h / -78 °C
View Scheme
iodobenzene
591-50-4

iodobenzene

4-CF3C6H4COCr(CO)5(1-)NMe4(1+)

4-CF3C6H4COCr(CO)5(1-)NMe4(1+)

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: 52 percent / diethyl ether; tetrahydrofuran / 16 h / 20 °C
2.1: BCl3 / CH2Cl2 / 5 h / -41 °C
2.2: 82 percent / Et3N / CH2Cl2 / 14 h / 20 °C
3.1: 95 percent / aq. NaOH / Pd[P(t-Bu)3]2 / tetrahydrofuran / 24 h / 60 °C
View Scheme
C17H20MgNSi

C17H20MgNSi

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: 52 percent / diethyl ether; tetrahydrofuran / 16 h / 20 °C
2.1: BCl3 / CH2Cl2 / 5 h / -41 °C
2.2: 82 percent / Et3N / CH2Cl2 / 14 h / 20 °C
3.1: 95 percent / aq. NaOH / Pd[P(t-Bu)3]2 / tetrahydrofuran / 24 h / 60 °C
View Scheme
E-(Et)(C6H5)CC(C6H5)(SiMe2C5H4N)
624731-31-3

E-(Et)(C6H5)CC(C6H5)(SiMe2C5H4N)

(E)-tamoxifen
13002-65-8

(E)-tamoxifen

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: BCl3 / CH2Cl2 / 5 h / -41 °C
1.2: 82 percent / Et3N / CH2Cl2 / 14 h / 20 °C
2.1: 95 percent / aq. NaOH / Pd[P(t-Bu)3]2 / tetrahydrofuran / 24 h / 60 °C
View Scheme
(E)-tamoxifen
13002-65-8

(E)-tamoxifen

rel-(1R,2S)-1-<4-<2-(dimethylamino)ethoxy>phenyl>-1,2-diphenylbutane
109640-21-3

rel-(1R,2S)-1-<4-<2-(dimethylamino)ethoxy>phenyl>-1,2-diphenylbutane

Conditions
ConditionsYield
With ammonium formate; palladium on activated charcoal In ethanol at 80℃; for 4.5h;83%
(E)-tamoxifen
13002-65-8

(E)-tamoxifen

tamoxifen
10540-29-1

tamoxifen

Conditions
ConditionsYield
With trifluorormethanesulfonic acid In dichloromethane at 0℃; for 3h;51%
With trifluorormethanesulfonic acid In dichloromethane at 0℃; for 3h;51%
With pyridine; bromine In diethyl ether; dichloromethane for 2h; Ambient temperature; Irradiation; Yield given;

13002-65-8Relevant academic research and scientific papers

Rh-Catalyzed Coupling of Aldehydes with Allylboronates Enables Facile Access to Ketones

Zhang, Kezhuo,Huang, Jiaxin,Zhao, Wanxiang

supporting information, (2022/02/21)

We present herein a novel strategy for the preparation of ketones from aldehydes and allylic boronic esters. This reaction involves the allylation of aldehydes with allylic boronic esters and the Rh-catalyzed chain-walking of homoallylic alcohols. The key to this successful development is the protodeboronation of alkenyl borylether intermediate via a tetravalent borate anion species in the presence of KHF2 and MeOH. This approach features mild reaction conditions, broad substrate scope, and excellent functional group tolerance. Mechanistic studies also supported that the tandem allylation and chain-walking process were involved.

Stereoconvergent and -divergent synthesis of tetrasubstituted alkenes by nickel-catalyzed cross-couplings

Zell, Daniel,Kingston, Cian,Jermaks, Janis,Smith, Sleight R.,Seeger, Natalie,Wassmer, Jana,Sirois, Lauren E.,Han, Chong,Zhang, Haiming,Sigman, Matthew S.,Gosselin, Francis

supporting information, p. 19078 - 19090 (2021/11/22)

We report the development of a method to diastereoselectively access tetrasubstituted alkenes via nickel-catalyzed Suzuki-Miyaura cross-couplings of enol tosylates and boronic acid esters. Either diastereomeric product was selectively accessed from a mixture of enol tosylate starting material diastereomers in a convergent reaction by judicious choice of the ligand and reaction conditions. A similar protocol also enabled a divergent synthesis of each product isomer from diastereomerically pure enol tosylates. Notably, high-throughput optimization of the monophosphine ligands was guided by chemical space analysis of the kraken library to ensure a diverse selection of ligands was examined. Stereoelectronic analysis of the results provided insight into the requirements for reactive and selective ligands in this transformation. The synthetic utility of the optimized catalytic system was then probed in the stereoselective synthesis of various tetrasubstituted alkenes, with yields up to 94% and diastereomeric ratios up to 99:1 Z/E and 93:7 E/Z observed. Moreover, a detailed computational analysis and experimental mechanistic studies provided key insights into the nature of the underlying isomerization process impacting selectivity in the cross-coupling.

Pd-catalyzed cross-coupling of highly sterically congested enol carbamates with grignard reagents via c-o bond activation

Chen, Zicong,So, Chau Ming

, p. 3879 - 3883 (2020/06/08)

The palladium-catalyzed cross-coupling reaction of enol carbamates to construct highly sterically congested alkenyl compounds is presented for the first time. This protocol demonstrates the potential of using thermally stable and highly atom-economic enol electrophiles as building blocks in bulky alkene synthesis. This reaction accommodates a broad substrate scope with excellent Z/E isomer ratios, which also provides a new synthetic pathway for accessing Tamoxifen.

Iterative synthesis of alkenes by insertion of lithiated epoxides into boronic esters

Bojaryn, Kevin,Fritsch, Stefan,Hirschhaüser, Christoph

supporting information, p. 2218 - 2222 (2019/04/10)

The insertion of lithiated epoxides into boronic esters followed by thermal syn-elimination provides a stereospecific entry to alkenes. This process avoids transition metals and is amenable to iteration to provide higher substitution patterns.

An atom efficient synthesis of tamoxifen

Heijnen, Dorus,Van Zuijlen, Milan,Tosi, Filippo,Feringa, Ben L.

supporting information, p. 2315 - 2320 (2019/03/06)

The direct carbolithiation of diphenylacetylenes and their cross-coupling procedure taking advantage of the intermediate alkenyllithium reagents are presented. By employing our recently discovered highly active palladium nanoparticle based catalyst, we were able to couple an alkenyllithium reagent with a high (Z/E) selectivity (10:1) and good yield to give the breast cancer drug tamoxifen in just 2 steps from commercially available starting materials and with excellent atom economy and reaction mass efficiency.

Photoredox-Catalyzed C-H Arylation of Internal Alkenes to Tetrasubstituted Alkenes: Synthesis of Tamoxifen

Wang, Quannan,Yang, Xiaoge,Wu, Ping,Yu, Zhengkun

supporting information, p. 6248 - 6251 (2017/11/24)

Visible-light-induced direct C-H arylation of S,S-functionalized internal alkenes, that is, α-oxo ketene dithioacetals and analogues, has been efficiently realized with aryldiazonium salts (ArN2BF4) as coupling partners and Ru(bpy)s

Photochemical Activation of Tertiary Amines for Applications in Studying Cell Physiology

Asad, Naeem,Deodato, Davide,Lan, Xin,Widegren, Magnus B.,Phillips, David Lee,Du, Lili,Dore, Timothy M.

supporting information, p. 12591 - 12600 (2017/09/23)

Representative tertiary amines were linked to the 8-cyano-7-hydroxyquinolinyl (CyHQ) photoremovable protecting group (PPG) to create photoactivatable forms suitable for use in studying cell physiology. The photoactivation of tamoxifen and 4-hydroxytamoxifen, which can be used to activate Cre recombinase and CRISPR-Cas9 gene editing, demonstrated that highly efficient release of bioactive molecules could be achieved through one- and two-photon excitation (1PE and 2PE). CyHQ-protected anilines underwent a photoaza-Claisen rearrangement instead of releasing amines. Time-resolved spectroscopic studies revealed that photorelease of the tertiary amines was extremely fast, occurring from a singlet excited state of CyHQ on the 70 ps time scale.

Divergent Synthetic Access to E- and Z-Stereodefined All-Carbon-Substituted Olefin Scaffolds: Application to Parallel Synthesis of (E)- and (Z)-Tamoxifens

Ashida, Yuichiro,Honda, Atsushi,Sato, Yuka,Nakatsuji, Hidefumi,Tanabe, Yoo

, p. 73 - 89 (2017/02/10)

A highly substrate-general synthesis of all-carbon-substituted E- and Z-stereodefined olefins is performed. The method comprises two sets of parallel and stereocomplementary preparations of (E)- and (Z)-α,β-unsaturated esters involving two robust and distinctive reactions: 1) stereocomplementary enol tosylations using readily available TsCl/diamine/(LiCl) base reagents, and 2) stereoretentive Negishi cross-coupling using the catalysts [Pd(dppe)Cl2] (for E) and [Pd(dppb)Cl2] (for Z). The present parallel approach is categorized as both type I (convergent approach: 16 examples, 56–87 % yield) and type II (divergent approach: 18 examples, 70–95 % yield). The obtained (E)- and (Z)-α,β-unsaturated ester scaffolds are successfully transformed into various E- and Z-stereodefined known and novel olefins (8×2 derivatization arrays). As a demonstration, application to the parallel synthesis of both (E)- and (Z)-tamoxifens, a representative motif of all-carbon-substituted olefins, is accomplished in a total of eight steps with an overall yield of 58 % (average 93 %) and 57 % (average 93 %), respectively.

Transition-Metal-Free α-Arylation of Enolizable Aryl Ketones and Mechanistic Evidence for a Radical Process

Pichette Drapeau, Martin,Fabre, Indira,Grimaud, Laurence,Ciofini, Ilaria,Ollevier, Thierry,Taillefer, Marc

, p. 10587 - 10591 (2015/09/02)

The α-arylation of enolizable aryl ketones can be carried out with aryl halides under transition-metal-free conditions using KOtBu in DMF. The α-aryl ketones thus obtained can be used for step- and cost-economic syntheses of fused heterocycles and Tamoxifen. Mechanistic studies demonstrate the synergetic role of base and solvent for the initiation of the radical process.

Nickel-catalyzed three-component domino reactions of aryl grignard reagents, alkynes, and aryl halides producing tetrasubstituted alkenes

Xue, Fei,Zhao, Jin,Hor, T. S. Andy,Hayashi, Tamio

supporting information, p. 3189 - 3192 (2015/03/30)

Three-component reaction of aryl Grignard reagents, alkynes, and aryl halides in the presence of 1 mol % of NiCl2 proceeded sequentially through carbomagnesiation of the alkyne followed by cross-coupling of the resulting alkenyl Grignard reagent with aryl halide to give tetrasubstituted alkenes in high yields.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 13002-65-8